

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

Cytokeratin, pan Antibody (AE-1/AE-3) [Alexa Fluor® 532]

RRID:AB_2924722

Type: Antibody

Proper Citation

Novus Cat# NBP2-33200AF532, RRID:AB_2924722

Antibody Information

URL: http://antibodyregistry.org/AB_2924722

Proper Citation: Novus Cat# NBP2-33200AF532, RRID:AB_2924722

Target Antigen: Cytokeratin, pan

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Flow (Intracellular), CyTOF-ready, Single Cell Western, Dual RNAscope ISH-IHC

Antibody Name: Cytokeratin, pan Antibody (AE-1/AE-3) [Alexa Fluor® 532]

Description: This monoclonal targets Cytokeratin, pan

Target Organism: Human, Rat, Bovine, Monkey, Rabbit, Zebrafish, Canine, Reptile, Mouse, Chicken

Clone ID: AE-1/AE-3

Antibody ID: AB_2924722

Vendor: Novus

Catalog Number: NBP2-33200AF532

Record Creation Time: 20231110T031318+0000

Record Last Update: 20260829T074146+0000

Ratings and Alerts

No rating or validation information has been found for Cytokeratin, pan Antibody (AE-1/AE-3) [Alexa Fluor® 532].

No alerts have been found for Cytokeratin, pan Antibody (AE-1/AE-3) [Alexa Fluor® 532].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hladik C, et al. (2026) Spatially Resolved Obesity-Driven Molecular Changes in Early Breast Cancer. The American journal of pathology, 196(7), 1471.

Liu SX, et al. (2025) Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell reports. Medicine, 6(7), 102200.

Salomó Coll C, et al. (2025) ER-phagy and proteostasis defects prime pancreatic epithelial state changes in KRAS-mediated oncogenesis. Developmental cell.

Knisely A, et al. (2025) Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(19), 4122.

Christensson G, et al. (2024) Spatial Multiomics Reveals Intratumoral Immune Heterogeneity with Distinct Cytokine Networks in Lung Cancer Brain Metastases. Cancer research communications, 4(11), 2888.

Caputo A, et al. (2024) Spatial Transcriptomics Suggests That Alterations Occur in the Preneoplastic Breast Microenvironment of BRCA1/2 Mutation Carriers. Molecular cancer research : MCR, 22(2), 169.

Reinstein ZZ, et al. (2024) Preexisting Skin-Resident CD8 and ?? T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy. Cancer discovery, 14(9), 1631.